Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd, is a biotechnology company that develops and commercializes novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs and Jelmyto for pyelocalyceal solution. The company pipeline products include UGN-102, which treats non-muscle invasive urothelial cancer; UGN-301 for High-grade non-muscle-invasive bladder cancer. UroGen Pharma is headquartered in Ra Anana, Israel.
UroGen Pharma Ltd premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
UGN-102: Low-Grade Intermediate Non-muscle Invasive Bladder Cancer |
UGN-301: High Grade Non-muscle Invasive Bladder Cancer |
Competitor Comparison
Key Parameters | UroGen Pharma Ltd | Esperion Therapeutics Inc | Orthopaedics Northeast PC | Monarch HealthCare Inc |
---|---|---|---|---|
Headquarters | Israel | United States of America | United States of America | United States of America |
City | Ra'Anana | Vero Beach | Angola | Irvine |
State/Province | Sharon (Netanya) | Florida | Indiana | California |
No. of Employees | 198 | 240 | - | - |
Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Arie Belldegrun, M.D | Chairman | Executive Board | - | 73 |
Elizabeth Barrett | Chief Executive Officer; Director | Executive Board | - | 60 |
Dong Kim | Chief Financial Officer | Senior Management | - | - |
Jason Smith | Chief Compliance Officer; General Counsel | Senior Management | - | - |
Mark P. Schoenberg, MD | Chief Medical Officer | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer